Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-743-6 | CAS number: 149-57-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In subchronic feeding studies, NOAEL's of approximately 200 and 300 mg/kg/day were established for mice and rats, respectively. Exposure to higher concentrations of 2-EHA was associated with growth retardation, increased liver weight and hepatocyte hypertrophy. In addition, in the highest dose groups decreased food consumption and body weights were observed. At the end of the recovery period (4 weeks), the observed changes had practically disappeared.
Key value for chemical safety assessment
Additional information
In another oral repeated dose toxicity study similar to OECD 408 (CMA, 1988), groups of ten male and female F344 rats were administeredfeed containing 0, 0.1, 0.5 or 1.5% (males: 0, 61, 303, 917 mg/kg bw; females: 0, 71, 360, 1068 mg/kg bw) 2-EHA for 91-93 consecutive days. Additional groups were assigned to satellite recovery groups and were fed diets containing either 0 or 1.5% 2-EHA for 94 days and then were offered standard diets for 27-28 days. Clinical abnormalities during this study consisted of porphyrin tears, porphyrin nasal discharge, alopecia, and urine-stained hair. These abnormalities were transient and were observed without relationship to treatment group. Body weights were reduced in both males and females in the 1.5% dietary group from the first week through study termination. By day 91, weights were reduced 8% in males and 10% in females. The lower body weights in the 1.5% dietary group paralleled reductions in feed consumption. Urine volumes were reduced in females at all treatment levels and specific gravity was increased only in females following consumption of the 1.5% diet. Minor hematological differences involving red blood cells included lower mean corpuscular haemoglobin (1.5% males and females and 0.5% males), mean corpuscular volume (1.5% females), and haemoglobin concentration (0.5% females). None of the changes were accompanied by evidence of anemia. Cholesterol levels were increased among groups of males in a dose-dependent manner (25, 42, and 78% for the 0.1, 0.5, and 1.5% dietary groups, respectively). Increases were also seen for 1.5% males in urea nitrogen (29%) and albumin (16%). Absolute liver weights in animals fed 1.5% diets were increased 32% in males and 19% in females. At the 0.5% dietary level, liver weights were increased 6-7% in both sexes. When liver weights were expressed relative to body weight, the increases were more pronounced at the 1.5% dietary level (44% in males, 33% in females) due to lower terminal body weights in those groups. Relative to body weight, 0.5% males and females had livers which were 6% and 8% heavier than those in the control group. Histopathology examination of livers revealed hypertrophy of hepatocytes and a decreased incidence of cytoplasmic vacuolization within hepatocytes in animals from the 1.5% and 0.5% dietary groups. Hypertrophy was seen in 10/10 1.5% males, 10/10 1.5% females, and 8/10 0.5% males. Reduction in hepatocyte cytoplasmic vacuolization was seen in 1.5% and 0.5% males and 1.5% females; incidences in these groups were 0-2 of 10 compared to 6 to 7 of 10 in respective control groups. Absolute kidney weights were not altered by treatment, but kidney weights relative to body weight were increased 5-13% in the 1.5% male and female groups and the 0.5% female group. Minor increases in relative weight of brain, adrenals and testes in 1.5% animals reflected lower terminal body weights in that group. No renal effects were detected histologically. Toxicity seen following 91-94 days of consumption of diets containing 2-EHA was reversible within 28 days of recovery. Histopathology findings in recovery animals were restricted to minimal bile duct hyperplasia in both control and treatment animals. Hepatocyte hypertrophy and decreased hepatocyte vacuolization, both of which were seen in non-recovery animals, were not observed in recovery animals. No substance-related renal effects were observed in recovery groups. Based on the observed effects, the NOAEL was 0.5% for males and females (ca. 303 and 360 mg/kg bw).
Justification for classification or non-classification
Based on the available data, classification for repeated dose toxicity is not warranted according to EU Directive 67/548/EEC and EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.